FRANKFURT, Germany--(BUSINESS WIRE)--Synexus, the world’s leading Site Management Organisation (SMO), dedicated to the recruitment of patients’ and hands-on conduct of clinical trials on behalf of pharmaceutical, biotech and CRO clients, today celebrated the opening of a new Dedicated Clinical Research Site in Frankfurt. The state-of-the-art expansion into new facilities in Frankfurt supports the global Synexus mission to be the patient’s choice for clinical research and to offer customers efficiency in the clinical trial process by recruiting more engaged patients from more capable sites.
At the formal opening of the new Synexus Frankfurt Clinical Research Site, Dr Christophe Berthoux, CEO of Synexus, was joined by Christoph Dietrich, the Managing Director of Synexus Germany and by Nicole Freibott, Head of the Synexus Frankfurt Clinical Research Site. Representatives of pharma, CRO, partner GPs and specialists were present to celebrate this important occasion and to reiterate the company’s long term plans to build service capability in this country where pharmaceutical and biotech companies are continuing to conduct a large number of clinical trials.
The opening, attended by clients, network doctors and business partners, was performed by Christophe Berthoux, CEO of Synexus, who commented “Germany is one of our leading locations for running clinical trials with its excellent medical expertise, a history of running high quality clinical trials and good access to patients. Europe continues to be a favored region for our clients in the running of their global clinical trials and we are planning to further develop our business in Germany.”
Synexus is a world leader in recruiting patients for clinical trials at its own dedicated research sites across Europe, Africa and the USA and has substantial presence with five research clinics in Germany.
Synexus German Managing Director Christoph Dietrich commented: “This is a further step in our plan to update and expand our very successful network of clinics across Germany by providing modern clinics which benefit both our patients and our clients. Our success in bringing clinical trials to Germany is dependent on our ability to deliver engaged patients and high quality data. We have put in place a proven patient engagement program which improves the patient experience and it is these added-value extras which really pay dividends in terms of client success.”
The new clinic, which will be managed by Nicole Freibott, is placed ideally for easy patient access as it is located in the inner city, close to the popular shopping street Zeil with immediate access to public transport and parking facilities.
Notes to Editors:
Synexus, is the world’s leading Site Management Organization (SMO), dedicated to patient recruitment and running of clinical trials by full time GCP trained investigators at its own clinical trial sites across the globe on behalf of pharmaceutical, biotech and CRO clients. Synexus operates a global network of 31 Dedicated Research Sites (DRS) in 10 countries focusing on cardiovascular, metabolic (diabetes and obesity), musculoskeletal, respiratory, CNS (dementia and pain) and infectious diseases including vaccines. Synexus also works with affiliated sites to meet the increasing demands of the Pharma industry. Dedicated patient engagement and project management teams support patient recruitment and execution of clinical studies across all the sites.
Synexus Dedicated Research Sites in Germany
Synexus Frankfurt, Bleichstraße 55 (Im Turmcarrée), 60313 Frankfurt
Synexus Berlin, Janusz-Korczak-Str. 8, 12627 Berlin
Synexus Bochum, Harmoniestraße 1 (Kortumhaus), 44787 Bochum
Synexus Leipzig, Johannisplatz 1, 04103 Leipzig
- ENDS -